Continuous glucose monitoring is associated with lower mortality in type 2 diabetes with basal insulin

{
  "signal_id": "564808ca-dd25-21d7-3956-2ee48ede1455",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-01T17:05:29+00:00",
  "company": {
    "name": "Abbott",
    "domain": "abbott.com"
  },
  "data": {
    "url": "https://isanidad.com/388740/la-monitorizacion-continua-de-glucosa-se-asocia-con-menor-mortalidad-en-diabetes-tipo-2-con-insulina-basal/",
    "title": "Continuous glucose monitoring is associated with lower mortality in type 2 diabetes with basal insulin - iSanidad",
    "excerpt": "Editorial Continuous glucose monitoring (CGM) is associated with a lower risk of mortality and cardiovascular complications in adults with type 2 diabetes treated with basal insulin. This is shown by new data announced by Abbott and presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held in Milan.A real-world study observed that CGM use was associated with a 45% lower risk of mortality at 12 months and a 36% lower risk at 24 months. The research evaluated nearly 28,000 adults with type 2 diabetes treated with basal insulin.A second independent study, conducted in France with more than 253,000 people with type 2 diabetes, also showed a reduction in hospitalizations for acute diabetes episodes among users of Libre technology.The study on mortality and cardiovascular outcomes analyzed a large database of electronic health records from the United States. Its objective was to evaluate long-term outcomes in adults with type 2 diabetes treated with basal insulin. Researchers matched nearly 28,000 adults, including approximately 14,000 CGM users and 14,000 people who did not use these systems. To do so, they considered 29 baseline characteristics and performed different sensitivity analyses. The work employed a target trial emulation approach. This methodology is designed to more accurately reproduce the conditions of a randomized...",
    "product": "Libre Assist",
    "summary": "Abbott has developed Libre Assist, a new AI-powered feature for its application that estimates how certain foods may affect glucose levels, though it is not yet available in Spain.",
    "planning": true,
    "image_url": "https://isanidad.com/wp-content/uploads/2026/10/closeup-shot-doctor-with-rubber-gloves-taking-blood-test-from-patient-scaled.jpg",
    "confidence": 0.9,
    "product_data": {
      "name": "Libre Assist",
      "full_text": "Libre Assist, a new feature of its application that combines artificial intelligence with CGM",
      "fuzzy_match": false,
      "release_type": "feature"
    },
    "product_tags": [
      "online_technology",
      "general_technology",
      "future_tech",
      "medical",
      "mobile"
    ],
    "published_at": "2026-10-01T17:05:29Z",
    "article_sentence": "The company has also showcased Libre Assist, a new feature of its application that combines artificial intelligence with CGM to estimate how certain foods may affect glucose levels."
  }
}

curl https://signals.autobound.ai/v1/signals/564808ca-dd25-21d7-3956-2ee48ede1455 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbott.com","limit":20}'